Executive Summary : | Recently, the “Government of India” has initiated "Atmanirbhar Bharat Abhiyaan" to develop and commercialize indigenous materials, methods, and technologies to make the country and its citizens independent and self-reliant in all senses. Considering this, we are proposing the development of sustainable base metal (Mn and Co) nanoparticles embedded in novel N-doped renewable carbon, catalysts (Mn@N-C and Co@N-C) for the synthesis of a wide range of amines, N-methylated amines, and substituted alcohols including pharmaceutical intermediates via catalytic transfer hydrogenation methodology using methanol as a hydrogen and C1 source. The proposal offers the synthesis of 3-Fluoro-4-morpholinobenzenamine (API for linezolid), 2,2'-(ethane-1,2-diyl)dianiline (API for Oxcarbazepine), 1-(3,5-bis(trifluoromethyl)phenyl)ethanol (API for Aprepitant) and 3-amino-1-phenyl-1- propanol (API for Fluoxetine), in 50g scale using our new process. These intermediates are identified by the Government of India to develop an indigenous method. Further, the study will be extended to the development of 2-(3,4-dimethoxyphenyl)ethanamine (API for Tetrabenazine), and 2-(5-Methoxy-1H-indol-3-yl)ethanamine(5-Methoxytryptamine) (intermediate for Melatonin) to extend the scope of the methodology for potentially important substrates. We also include challenging commercially important molecules such as Cinnamaldehyde, 3-Nitro-L-tyrosine, 3-Nitrostyrene, and 2-Chloro-4-nitrohenol, for the reductive transformations. Hydrogenation of biomass-derived Furfuraldehyde (FA), 5-Methyl-2-furaldehyde (MF), and 5-hydroxymethylfurfural (5-HMF) possesses tremendous industrial applications for the production of resins, polymers, foams, drug intermediates, plasticizers, adhesives, artificial fibers, diols, fragrances, biodiesel, green solvents, fine chemicals; hence these will be considered for the reductive transformation. The study of reaction mechanism, complete mass & energy balance, and preliminary cost-benefit evaluation are part of the project scope. The proposal also offers the development of deuterium-labeled pharmaceuticals using our newly developed catalyst and CD3OD (as a deuterium source). The process will be optimized for the deuteration of nitro, nitrile, and carbonyl compounds followed by the synthesis of deuterium-labeled intermediates such as (4-Chlorphenyl)-phenylmethanol (API for Buclizine), 2-(3,4-dimethoxyphenyl)ethanamine) (API for Deutetrabenazine) and methyl 4-(R)-hydroxy-4-phenylbutyrate (API for Norfluoxetine) in 10g scale. |